About: In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19
Creator	Hammer, Mark Hornick, Jason Kanjilal, Sanjat Padera, Robert Schaefer, Inga-Marie Sholl, Lynette Solomon, Isaac
topic	covid:71280d857afcbea02da4544abdd64bbf9486d62c#this
Source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has led to a global public health crisis. In elderly individuals and those with comorbidities, COVID-19 is associated with high mortality, frequently caused by acute respiratory distress syndrome. We examine in situ expression of SARS-CoV-2 in airways and lung obtained at autopsy of individuals with confirmed COVID-19 infection. Seven autopsy cases (male, N = 5; female, N = 2) with reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infection and a median age of 66 years (range, 50–77 years) were evaluated using a rabbit polyclonal antibody against SARS Nucleocapsid protein in correlation with clinical parameters. The median time from symptom onset to death was 9 days (range, 6–31 days), from hospitalization 7 days (range, 1–21 days), from positive RT-PCR 7 days (range, 0–18 days), and from intensive care unit admission defining onset of respiratory failure 3 days (range, 1–18 days). Chest imaging identified diffuse airspace disease in all patients corresponding to acute and (N = 5) or organizing (N = 2) diffuse alveolar damage (DAD) on histologic examination. Among five patients with acute-phase DAD (≤7 days from onset of respiratory failure), SARS-CoV-2 was detected in pulmonary pneumocytes and ciliated airway cells (N = 5), and in upper airway epithelium (N = 2). In two patients with organizing DAD (>14 days from onset of respiratory failure), no virus was detected in lungs or airways. No endothelial cell infection was observed. The findings suggest that SARS-CoV-2 infection of epithelial cells in lungs and airways of patients with COVID-19 who developed respiratory failure can be detected during the acute phase of lung injury and is absent in the organizing phase.
has issue date	2020-06-19(xsd:dateTime)
bibo:doi	10.1038/s41379-020-0595-z
bibo:pmid	32561849
has license	no-cc
sha1sum (hex)	71280d857afcbea02da4544abdd64bbf9486d62c
schema:url	https://doi.org/10.1038/s41379-020-0595-z
resource representing a document's title	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19
has PubMed Central identifier	PMC7304376
has PubMed identifier	32561849
schema:publication	Mod Pathol
resource representing a document's body	covid:71280d857afcbea02da4544abdd64bbf9486d62c#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/71280d857afcbea02da4544abdd64bbf9486d62c
is schema:about of	named entity 'COVID-19' named entity 'organizing' named entity 'caused' named entity 'observed' named entity 'airspace' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'range' named entity 'organizing' named entity 'individuals' named entity 'patients' named entity 'airways' named entity 'situ' named entity 'lung injury' named entity 'range' named entity 'ciliated' named entity 'SARS-CoV-2' named entity 'In situ' named entity 'ciliated' named entity 'respiratory failure' named entity 'global public health' named entity 'lung' named entity 'SARS-CoV-2' named entity 'endothelial cell' named entity 'acute phase' named entity 'COVID' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'autopsy' named entity 'diffuse alveolar damage' named entity 'autopsy' named entity 'reverse transcriptase' named entity 'infection' named entity 'DAD' named entity 'polymerase chain reaction' named entity 'altered mental status' named entity 'alveolar spaces' named entity 'viral tropism' named entity 'COVID' named entity 'Institutional Review Board' named entity 'nucleocapsid protein' named entity 'St. Louis' named entity 'PU.1' named entity 'SARS' named entity 'pressure cooker' named entity 'Presenting symptoms' named entity 'staining' named entity '21 days' named entity 'ground-glass opacities' named entity 'comorbidities' named entity 'type 2' named entity 'monoclonal antibodies' named entity 'SARS-CoV-2' named entity 'nasopharynx' named entity 'COVID' named entity 'cough' named entity 'virus' named entity 'tropism' named entity 'IHC' named entity 'Histologic examination' named entity 'Novus Biologicals' named entity 'Downregulation' named entity 'macrophages' named entity 'pneumocytes' named entity 'case fatality rate' named entity 'infection' named entity 'infection' named entity 'DAD' named entity 'IHC' named entity 'influenza' named entity 'SARS-CoV-2' named entity '229E'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software